Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update

Provided By GlobeNewswire

Last update: Aug 1, 2024

Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency